This application for re-selection as a Diabetes TrialNet Clinical Center consists of a leadership statement outlining our perspective and approach to address TrialNet's current challenges. It also describes our Clinical Center's current and planned activities to accomplish TrialNet's mission including innovative approaches to collaboratively and efficiently achieving our overarching goal - delaying and preventing the onset of clinical type 1 diabetes. The TrialNet Northwest Clinical Center recruitment region encompasses Alaska, Washington, Oregon, Idaho, and Montana. We work with more than a dozen Affiliate sites, local and regional T1D advocacy groups and diabetes health care providers to assure that those with T1D are aware that their relatives are at risk for disease and that screening along with the possibility of prevention trials through TrialNet are available. We also have significant recruitment efforts using digital media, including the use of websites, Facebook, Twitter, to convey information and foster discussion. More than 7500 individuals in our region have been screened for risk. TrialNet Northwest Clinical Center team members are active participants and are in leadership roles in the TrialNet network. We plan to work collaboratively within the new TrialNet structure to prevent or delay type 1 diabetes.
TrialNet is an international network with the primary aim of delaying or preventing type 1 diabetes. This is an application from Dr. Greenbaum and the Benaroya Research Institute to continue as the Type 1 Diabetes TrialNet Northwest Clinical Center and conduct clinical trials to stop type 1 diabetes. Our recruitment region encompasses Alaska, Washington, Oregon, Idaho, and Montana.
|Redondo, Maria J; Geyer, Susan; Steck, Andrea K et al. (2018) A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk. Diabetes Care 41:1887-1894|
|Greenbaum, Carla J; Speake, Cate; Krischer, Jeffrey et al. (2018) Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetes-The TrialNet Experience. Diabetes 67:1216-1225|
|Haller, Michael J; Schatz, Desmond A; Skyler, Jay S et al. (2018) Low-Dose Anti-Thymocyte Globulin (ATG) Preserves ?-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes. Diabetes Care 41:1917-1925|
|Redondo, Maria J; Geyer, Susan; Steck, Andrea K et al. (2018) TCF7L2 Genetic Variants Contribute to Phenotypic Heterogeneity of Type 1 Diabetes. Diabetes Care 41:311-317|
|Sosenko, Jay M; Geyer, Susan; Skyler, Jay S et al. (2018) The influence of body mass index and age on C-peptide at the diagnosis of type 1 diabetes in children who participated in the diabetes prevention trial-type 1. Pediatr Diabetes 19:403-409|
|Ismail, Heba M; Xu, Ping; Libman, Ingrid M et al. (2018) The shape of the glucose concentration curve during an oral glucose tolerance test predicts risk for type 1 diabetes. Diabetologia 61:84-92|
|Culina, Slobodan; Lalanne, Ana Ines; Afonso, Georgia et al. (2018) Islet-reactive CD8+ T cell frequencies in the pancreas, but not in blood, distinguish type 1 diabetic patients from healthy donors. Sci Immunol 3:|
|Vecchio, Federica; Lo Buono, Nicola; Stabilini, Angela et al. (2018) Abnormal neutrophil signature in the blood and pancreas of presymptomatic and symptomatic type 1 diabetes. JCI Insight 3:|
|Redondo, Maria J; Steck, Andrea K; Sosenko, Jay et al. (2018) Transcription Factor 7-Like 2 (TCF7L2) Gene Polymorphism and Progression From Single to Multiple Autoantibody Positivity in Individuals at Risk for Type 1 Diabetes. Diabetes Care 41:2480-2486|
|Sanda, Srinath; Type 1 Diabetes TrialNet Study Group (2018) Increasing ICA512 autoantibody titers predict development of abnormal oral glucose tolerance tests. Pediatr Diabetes 19:271-276|
Showing the most recent 10 out of 72 publications